NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/07/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization564.53 mln
Float27.59 mln
Earnings Date08/18/2026
Piotroski F-Score
4
/ 9
Borderline
Relative Strength
96
/ 100
Top performer
Debt / Equity
0.03
Debt-free
ROE
-27.89
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Contineum Therapeutics is a San Diego-based clinical-stage company focused on developing small-molecule drugs to treat neurological, inflammatory, and immune system disorders. Its lead drug candidate, PIPE-791, targets a specific receptor in the brain and is being studied as a potential treatment for idiopathic pulmonary fibrosis and chronic pain. The company is also advancing PIPE-307, which works through a different receptor mechanism and is being evaluated for depression and relapsing-remitting multiple sclerosis. Formerly known as Pipeline Therapeutics, the company adopted its current name in November 2023 and has been operating since 2009.
